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Abstract
Background: Women with Li- Fraumeni syndrome (LFS) have elevated breast 
cancer (BC) risk. Optimal BC treatment strategies in this population are yet 
unknown.
Methods: BC subtypes and treatment were retrospectively investigated between 
December 2016 and January 2019 in a multicentre study. BC risks were evaluated 
according to the type of surgery.
Results: Thirty- five women of our study population (35/44; 79.5%) had developed 
36 breast lesions at first diagnosis at a mean age of 34 years. Those breast lesions 
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1  |  INTRODUCTION
Li- Fraumeni syndrome (LFS, MIM 151623) is a rare 
and highly penetrant cancer predisposition syndrome 
characterised by a broad cancer spectrum and caused 
by pathogenic/likely pathogenic (P/LP) germline vari-
ants in the TP53 tumour suppressor gene.1– 4 Since TP53 
is included on gene panels offered to women with sus-
pected hereditary breast and ovarian cancer (HBOC), 
P/LP TP53 variant carriers are increasingly identified 
among women not meeting current LFS testing crite-
ria.1– 3,5 Given the fact that not all patients with LFS 
are being diagnosed the precise number is unknown. 
Based on published population prevalence estimates of 
TP53  germline variants, we estimate that the number 
within Germany is around 15000.6 P/LP in TP53 are 
detected in up to 7.7% of women with breast cancer 
(BC) younger than 31 and in <1% of BC patients inde-
pendent of family history or age.7– 14 A recent analysis 
showed a low prevalence of 0.05% for TP53  germline 
variants in BC patients and its association with BC.15 
Women with LFS face a lifetime BC risk of >50% by age 
of 70, typically diagnosed in women under the age of 31 
and often occurs as synchronous bilateral or metachro-
nous contralateral BC and comes with a general cancer 
risk of up to 100%.2,5,10,11,15– 19 In case of a BC diagnosis 
under the age of 35, annual rates of contralateral BC are 
almost twice as high among women with LFS compared 
to female carriers of a P/LP variant in BRCA1 or BRCA2 
(7.0% vs. 3.6% or 2.6%).17 Based on these BC risks and 
considering the risk for other LFS- associated cancers 
such as sarcomas, adrenocortical carcinoma, brain tu-
mours or leukaemia, international experts recommend 
a comprehensive cancer surveillance programme in-
cluding annual whole body and breast magnetic reso-
nance imaging (MRI).20,21 In cancer- free women with 
LFS, bilateral prophylactic mastectomy (BPM) can be 
considered. In a case of BC diagnosis in a patient with 
LFS, the knowledge about a P/LP TP53 germline vari-
ant influences the therapeutic approach as radiation 
and its risk to induce secondary malignancies should be 
discussed.22– 25 Mastectomy (ME) and contralateral pro-
phylactic mastectomy (CPM) might be options to pre-
vent local BC recurrence or contralateral BC.17,22,26,27 
There is little evidence about surgical approaches, pro-
phylactic operations (PO) and LFS- specific BC char-
acteristics besides the described high frequency of 
HER2- amplified BC subtypes.15,25,28– 32 To date, LFS is 
not addressed concretely in the German BC S3 guide-
line. Recent clinical approaches are based on interna-
tional recommendations and best experts’ opinions. 
Here, we retrospectively reviewed pathological and 
clinical aspects of primary LFS- associated BCs and of 
a second BC diagnosis. We analysed breast surgery in 
respect to surgical techniques and related local recur-
rence rates in women with LFS in Germany.
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und Forschung, Federal Ministry 
of education and research, BMBF 
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comprised 32 invasive BCs (89%), three ductal carcinoma in situ alone (8%) and 
one malignant phyllodes tumour (3%). BCs were mainly high- grade (18/32), of 
no special type (NST; 31/32), HER2- enriched (11/32) or luminal- B- (like)- type 
(10/32). Affected women (n  =  35) received breast- conserving surgery (BCS, 
n = 17) or a mastectomy (ME, n = 18) including seven women with simultaneous 
contralateral prophylactic mastectomy (CPM) at first diagnosis. Nineteen women 
suffered 20 breast or locoregional axillary lesions at second diagnosis with mean 
age of 36. Median time between first and second diagnosis was 57 months; me-
dian time to contra- and ipsilateral recurrence depended on surgical strategies 
(BCS: 46 vs. unilateral ME: 93 vs. bilateral ME > 140 months). Women with a pri-
mary treatment of solitaire therapeutic ME suffered from contralateral BC earlier 
compared to those with therapeutic ME and CPM (median: 93 vs. >140 months).
Conclusion: Aggressive BC subtypes occur among women with LFS. Surgical 
treatment, i.e. ME and CPM, may prolong time to a second BC diagnosis. 
Conclusion on long- term survival benefit is pending. Individual competing tu-
mour risks and long- term outcomes need to be taken into consideration.
K E Y W O R D S
breast surgery, cancer predisposition, hereditary breast cancer, Li- Fraumeni syndrome, 
mastectomy, prophylactic surgery, TP53
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2  |  METHODS
2.1 | Study population and protocol
Women with a P/LP TP53 variant were identified and con-
tacted between December 2016 and January 2019 by coop-
erating centres. A subset of the cohort had participated in 
our previous study.33 As previously described, the number 
of contacted individuals were reported to the initiating 
centre in Heidelberg33: In brief, study information includ-
ing a study- specific questionnaire with a pseudonymised 
code was sent to eligible women. Study participants were 
included in the current retrospective analysis if complete 
clinical as well as pathology reports and informed written 
consents were available as well as filled questionnaires on 
prophylactic surgery. The study was approved by the insti-
tutional review board (S- 370/2016).
Pathological tumour stages were evaluated according 
to the American Joint Committee on Cancer Anatomic 
Stage Group. In case of BC recurrence with no axillary 
procedure, lymph node status was considered negative.34 
The detection of micrometastasis in lymph nodes was 
classified as nodal positive. Evaluation of hormone re-
ceptor (ER, PgR) and HER2 status, and scoring of Ki- 67 
was performed as routine diagnostic by local pathology 
institutes. Institutions were adherent to pertinent interna-
tional guidelines at the time of diagnosis, especially the 
WHO Classification of Tumours framework.35
The surrogate molecular subtype was determined accord-
ing to routine IHC results with Ki67 <20% as the threshold 
for the distinction between Luminal- A and Luminal- B sub-
types according to the St. Gallen guidelines 2013.36
2.2 | Satisfaction with 
prophylactic operations
The applied PO and its respective satisfaction i.e. any type 
of prophylactic mastectomy (PM, including BPM + CPM) 
and prophylactic bilateral salpingo- oophorectomy (PBSO) 
were evaluated with six self- designed questions. The re-
sponse categories ranged on a five- point scale from “ab-
solutely satisfied” to “totally unsatisfied”. In case of BC, 
we considered not only CPM in case of first BC but also 
secondary PM according to the patient´s choice due to the 
genetic test result or a second BC diagnosis.
2.3 | Statistical analyses
Statistical analyses and p- values and were considered to 
be mainly descriptive. We performed two- sided t- tests and 
Fisher- Yates tests to identify differences between groups. 
Survival analyses were assessed by estimation of Kaplan– 
Meier distributions and comparison of subgroups by log- 
rank tests. Using Kaplan– Meier curves, the time from first 
breast lesion to one of the following events: (1) ipsilateral 
BC and/or DCIS, (2) contralateral BC and/or DCIS, (3) 
both or (4) the end of observation time was evaluated and 
distributions in respect to the surgical techniques were 
compared. In a second step, only contralateral BC and/or 
DCIS events in formerly ME patients were considered in 
order to evaluate the potential benefits of a simultaneous 
CPM in case of BC and/or DCIS. If the month or day was 
excluded from the date in the medical records, we used 
January or the first of the month respectively for statis-
tical calculations. One participant with simultaneous bi-
lateral BC was excluded from these subanalyses. p- values 
<0.05 were considered statistically significant. We used 
Microsoft Excel Version 15.31 (170216) and SPSS 24 (SPSS 
Statistics V24, IBM Corporation).
3  |  RESULTS
3.1 | Study population, breast lesions 
at first diagnosis and their respective 
histopathology
The study population consisted of 44 women with LFS. 
Socio- demographic data and personal cancer history are 
shown in Table 1. Of the 44 women, eight women (18%) 
were healthy and one (2%) had a solitary cervical carci-
noma. Thirty- five women of the study population (35/44; 
80%) had 36 breast lesions (including invasive BC and 
non- invasive breast lesions) at a mean age of 34 years old 
(range: 22– 53 years). Thirty of these 35 women (86%) had 
primary unilateral invasive BC and one (3%) had synchro-
nous bilateral BC leading to a total number of 32 invasive 
BC lesions in 31 women. The remaining four women had 
singular ductal carcinoma in situ (DCIS: n = 3, 9%) or a 
malignant phyllodes tumour (n = 1, 3%; Figure 1).
At first diagnosis, invasive BCs (n  =  32, 91%) were 
mainly invasive carcinoma of no special type (NST: 
n = 31/32, 97%; with NST + DCIS: n = 10, 32% vs. NST 
alone: n = 21, 68%) and one medullary carcinoma (n = 1, 
3%). Tumours were mainly high- grade ductal (Grade 3: 
n = 18/32, 56%), HER2- enriched (n = 11/32, 34%) or of 
luminal- B- (like)- subtype (n = 10/32, 31%, Table 2).
3.2 | Primary therapy for breast lesions 
at first diagnosis
Among all 35 women with first diagnosed breast lesions, 
different kinds of surgery were applied based on tumour 
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board recommendations and patients’ decisions: Breast- 
conserving surgery (BCS: n = 17/35, 48%) was a common 
surgical approach. Another nine women received unilat-
eral (n = 8/35, 23%) or primary bilateral (n = 1/35, 3%) 
therapeutic ME. Secondary ME due to persistent positive 
surgical margins were performed in two (n  =  2/35, 6%) 
women. In addition, seven (n = 7/35, 20%) women were 
offered unilateral therapeutic ME with simultaneous 
CPM. This leads to a total number of 18 women receiv-
ing any kind of ME (either therapeutically or contralateral 
prophylactically) as the most common surgical procedure 
at first diagnosis. MEs were performed as skin- sparing 
(n = 8/18, 44%) or radically modified ME (n = 7/18, 39%) 
followed by nipple- sparing ME (n  =  2/18, 11%) and in 
one case (n = 1/18, 6%) no further specifications on sur-
gical techniques or breast reconstruction were given. 
11 women decided towards breast reconstruction: five 
women each chose primary breast implants (n  =  5/11, 
29%) or expander- implant reconstruction (n = 5/11, 29%), 
while one (n = 1/11, 6%) opted for a tissue flap procedure. 
Six women chose no breast reconstruction after ME.
Twenty women (n  =  20/35, 57%) received adjuvant 
radiotherapy of the breast and/or regional lymph nodes. 
Focusing on BCS at first diagnosis, radiation was applied 
in 14 (82%) out of 17 women with BCS, whereas two 
women (n  =  2/17, 12%) did not receive adjuvant radio-
therapy due to the LFS diagnosis. In one woman with BCS 
(n = 1/17, 6%) no information on adjuvant radiotherapy 
was available.
The LFS diagnosis was known prior to breast surgery 
in 2/17 women treated with BCS and in 9/18 women with 
any kind of ME while all other women received their ge-
netic testing result of a P/LP TP53 variant after surgery. 
Among these 9 women with any kind of ME and who 
were informed about the LFS diagnosis prior to breast sur-
gery, 1 woman chose bilateral therapeutic ME due to bilat-
eral BC, 6 had unilateral ME only and 2 had a unilateral 
therapeutic ME in combination with CPM.
Sentinel lymph node dissection (SLNB) was performed 
in 17 out of 35 women (n  =  17/35, 48%) while axillary 
lymph node dissection (ALND) was conducted in 13 
T A B L E  1  Clinical characteristics and cancer history of 44 
women with LFS
Study population, n = 44 n (%)






Single cervical cancer 1 (2)
Single BCa 12 (27)
Multiple BCb 14 (32)
Multiple BC + metachronous distant 
metastasis
2 (6)




Abbreviations: BC, breast cancer; SD, standard deviation.
aIncluding singular DCIS and malignant phyllodes tumour.
bIncluding synchronous or metachronous bilateral BC, BC/DCIS recurrence, 
and contralateral DCIS/BC.
cIncluding other primary cancers from the LFS spectrum.
F I G U R E  1  Flowchart of the study 
population distinguishing affected women 
and respective breast lesions at first 
diagnosis
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T A B L E  2  Invasive BC characteristics at first and second diagnosis in women with LFS. Data on singular DCIS n (first diagnosis) = 3; 
n (second diagnosis) = 4 and malignant phyllodes tumour n (first diagnosis) = 1 are not shown. At first diagnosis, one woman had 
simultaneous bilateral invasive breast cancer while 30 had unilateral BC leading to 32 invasive BC lesions in 31 affected women. At second 
diagnosis, one women had isolated invasive axillary recurrence and 15 women had unilateral invasive BC ± DCIS
Breast cancer characteristics
First diagnosis n (invasive breast cancer 
lesions) = 32 in 31 affected women
Second diagnosis n (invasive breast cancer 
lesions incl. one isolated invasive axillary 
recurrence) = 16 in 16 affected women
n (%) n (%)
Initial BC tumour sizea
≦2 cm 12 (38) 12 (75)
>2– 5 cm 18 (56) 3 (19)
>5 cm 1 (3) 0 (0)
Size after NACTb 1 (3) 0 (0)
Axillary recurrence alone — 1 (6)
Axillary nodal status
Negative 19 (59) 12 (75)
Positive 13 (41) 3 (19)
Axillary recurrence alone — 1 (6)
Pathological tumour stagec
0° 6 (19) 2 (12.5)
I 6 (19) 8 (50)
II 17 (53) 3 (19)
III 3 (9) 0 (0)
IV 0 (0) (0)
Axillary recurrence alone — 1 (6)
Only clinical stage indicated 0 (0) 2 (12.5)
Molecular subtypes by IHC
Luminal- A 4 (13) 3 (19)
Luminal- B 10 (31) 4 (25)
Triple- negative 5 (16) 1 (6)
HER2- positive 11 (34) 8 (50)
+ HR positive 10 (31) 5 (31)
− HR negative 1(3) 2 (13)
HR unknown 0 (0) 1 (6)
Unknown ✥ 2 (6) 0 (0)
Grading
1 1 (3) 1 (6)
2 13 (41) 8 (50)
3 18 (56) 5 (31)
N.I. 0 (0) 2 (13)
Note: n, number; N.I., not indicated; HR, hormone receptor; °comprises 2 DCIS (ypTis, ypN0) and six pathological complete remissions (ypT0, ypN0, pCR); 
IHC— immunohistochemistry; ✥ unknown— HR positive or negative BC without specification of HER2 status; Luminal- B- (like)- subtype was defined as 
hormone receptor positive, HER2 negative BC with high levels of Ki- 67.
aIn case of neoadjuvant systemic therapy (NACT) the initial clinical stage was evaluated/ in case of a primary operation only pathological stages were 
considered.
bNo initial clinical stage indicated, only the pathological stage after NACT was indicated in clinical reports.
cAccording to the AJCC Anatomic Stage Group (35).
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women (n  =  13/35, 37%) and secondary ALND in one 
(n = 1/35, 3%). The participant with simultaneous bilat-
eral invasive BC had SLNB on one side and ALND on the 
other side (n = 1/35, 3%) Two women with DCIS (n = 2, 
6%) and one with a phyllodes tumour (n = 1, 3%) did not 
have any axillary procedure.
Most women with invasive BC (n  =  28/31, 90%) re-
ceived chemotherapy ± anti- HER2 antibody therapy with 
neoadjuvant (n = 13, 46%) or adjuvant regimes (n = 15, 
54%).
3.3 | Ipsilateral locoregional 
recurrence and contralateral BC— 
second diagnosis
Nineteen women (n = 19/35, 54%) had 20 second breast or 
axillary lesions i.e. locoregional recurrence or a contralat-
eral diagnosis.
In detail, seven women (n = 7/35, 20%) had ipsilateral 
recurrence of invasive BC (in- breast: n = 6/35, 17%, ipsilat-
eral axillary recurrence: n = 1/35, 3%), and one (n = 1/35, 
3%) had ipsilateral (re)- occurrence of DCIS alone and si-
multaneous contralateral invasive BC.
In 11 women (n = 11/35, 31%) contralateral metachro-
nous BC or DCIS (only DCIS: n  =  3/35, 27%; invasive 
BC  ±  DCIS: n  =  8/35, 73%) occurred. Pathological and 
clinical characteristics of second invasive BCs (n= 16) are 
shown in Table 2 compared to the initial BC diagnosis.
Mean age at diagnosis of the second breast lesion was 
36  years old (range 24– 57  years). Median time between 
first and second diagnosis was 57  months (95% confi-
dence interval CI: 0.0– 114.5). Even though most women 
with ipsilateral in- breast recurrence had a previous BCS 
in opposite to those with prior unilateral therapeutic ME 
our findings were not statistically significant (n  =  5/17, 
29% vs. n = 1/10, 10%; p = 0.36, two- sided Fisher's exact 
test; one woman with ipsilateral axillary recurrence was 
excluded).
For surgical treatment of a second BC diagnosis, three 
out of these 19 women (16%) opted again for BCS (all of 
them had a metachronous contralateral BC) while thir-
teen (n  =  13/19, 68%) received some type of ME. One 
woman (n  =  1/19, 5%) with former therapeutic and 
nipple- sparing CPM had a nipple- areola complex excision 
due to contralateral BC in this region. Two patients (11%) 
did not undergo a re- surgical treatment at the time of data 
analysis due to an ongoing systemic treatment with che-
motherapy ± HER2- targeted therapy. SLNB or ALND was 
performed in 9 (47%) and 2 (11%) cases.
The operation technique influenced the time between 
first BC diagnosis to either ipsilateral BC and/or DCIS 
and/or contralateral BC and/or DCIS (Figure 2; Table 3). 
Patients opting for bilateral ME had a 70% probability of 
being recurrence- free over 140 months while those con-
sidering breast- conserving surgery or unilateral ME had 
only a chance of approximately 20% of being recurrence- 
free shortly after 120  months (Figure  2). Contralateral 
disease- free survival with respect to the type of ME (uni-
lateral therapeutic ME vs. unilateral therapeutic ME + si-
multaneous CPM) is presented in Figure 3 and Table 3.
3.4 | Other preventive surgery and 
satisfaction with surgical results
One woman with LFS opted for BPM in combination 
with a PBSO while 19 women with primary BC or a sec-
ond BC diagnosis underwent any kind of PO (n(any kind 
of PM) = 16, n(any kind of PM + PBSO) = 3). The satis-
faction with the surgical results is presented in Figure 4. 
We could see a tendency that women choosing PO were 
F I G U R E  2  Ipsi- and contralateral 
disease- free survival depending on type of 
surgery in women with LFS; we analysed 
the time between first diagnosis up to 
one of the events such as ipsilateral BC 
and/or DCIS, contralateral BC and/or 
DCIS, both or end of observation time; 
ME— mastectomy; the grey line marks the 
median time to recurrence on the x- axis: 
BCS: 46 vs. unilateral therapeutic ME: 
93 months vs. bilateral ME: >140 months; 
log- rank test p = 0.10
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slightly older than women without PO (39.7  ±  10.2 vs. 
37.8 ± 12.4 years; t- test p = 0.59).
4  |  DISCUSSION
This analysis is, to our knowledge, the first to address 
surgical BC treatment and risk- reducing surgery among 
women with LFS. In accordance with previous stud-
ies,25,28,29,31,32 we observed more aggressive BC sub-
types with high nuclear grade and positive HER2- status 
or luminal- B- (like)- phenotype in women with LFS, 
necessitating neo- or adjuvant- systemic therapy. At first 
diagnosis, 53% and 9% of affected women had pathologi-
cal tumour stages II or III, often nodal positive (41%). In 
case of recurrence, most women presented with lower 
tumour stages which might be due to intensified follow-
 up including breast MRI. The internationally recom-
mended LFS- specific cancer surveillance programmes 
were not applied prior to BC diagnoses for most subjects 
as in most cases the LFS diagnosis was unknown prior to 
the first BC diagnosis. In general, genetic analyses were 
performed as part of an HBOC multigene panel analysis 
including TP53.
F I G U R E  3  Contralateral disease- free survival depending on type of mastectomy (ME): For patients with unilateral therapeutic 
ME alone and unilateral therapeutic ME in combination with simultaneous contralateral ME (bilateral ME) we analysed the time from 
diagnosis of first BC and/or DCIS to contralateral BC and/or DCIS— one woman with primarily bilateral therapeutic ME was excluded for 
these subanalyses; ipsilateral events were taken as censored observations. The grey line marks the median time to recurrence on the x- axis: 
unilateral therapeutic ME: 93 months vs. unilateral therapeutic ME + CPM >140 months; log- rank test p = 0.19
F I G U R E  4  Satisfaction with prophylactic operation results; N.I., not indicated
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In our cohort, only 11 women (31%) with any kind of a 
breast lesion knew about their P/LP TP53 germline variant 
prior to their first oncological treatment. It has been previ-
ously emphasised that knowledge of a detailed family his-
tory preoperatively and rapid first priority genetic testing 
in “fast track mode” even before surgery can optimise care 
especially if LFS is suspected e.g. in women ≤30 years old 
and especially in HER2 enriched BC in young women and 
should be discussed prior to therapy.11,30,32 On the other 
hand, overburdening women with decision- making about 
secondary prophylactic measures in the temporal context 
of primary therapy must be considered and requires fur-
ther investigation.
In general, the LFS diagnosis influences BC treatment. 
Our data showed that the LFS diagnosis was rarely known 
prior to BCS. Normally, ME is discussed in order to avoid 
breast radiation after BCS due to the risk of radiation- 
induced secondary malignancies, such as sarcoma, small 
lung cancer or thyroid cancer, which is described in up to 
33% of individuals with LFS.22,23,25– 27 Furthermore, the risk 
of in- breast recurrence after radiation has been addressed 
previously by Heymann et al., who found an ipsilateral 
“in- field relapse” of BC in three out of six patients after a 
median follow- up of 6 years.23 A recent study by Le et al. 
with a follow- up of 12.5 years described a lower risk for 
locoregional BC recurrence in the chest wall after post- ME 
radiotherapy (n = 1/8, 13%) and for secondary malignan-
cies (sarcomas: n = 1/18, 6%; thyroid cancer: n = 1/18, 6%) 
and pointed out that there is no absolute contraindication 
for radiotherapy.25 In our cohort, all 7 women with ipsilat-
eral in- breast recurrence had former radiotherapy of the 
breast (5 women with former BCS + radiation and 2 with 
former ME  +  radiation, data not shown) thus probably 
supporting the finding of Heymann et al.. Even in case of 
a second BC disease, 16% of our affected study participants 
opted again for BCS. Time after last radiation varied due to 
individual treatment schedules and was not further stud-
ied. Adjuvant radiation is generally recommended to start 
within 8 weeks after BC surgery according to the German 
national S3  guideline with no differentiation or further 
specifications for individuals with LFS.37 At most centres, 
radiation is typically offered 4– 8 weeks after surgery. Its 
precise impact ought to be addressed in further studies. 
These findings emphasise that individual treatment strat-
egies for LFS- BC patients are necessary, especially before 
≤30 years or in young Her2 positive BC patients. Though 
most participants had no knowledge on their TP53 status 
at first diagnosis the next surgery should take this infor-
mation into account and adapt individual treatment strat-
egies. Further studies with larger collectives e.g. through 
registers in order to achieve LFS- specific surgical, radi-
ation and systemic protocols are needed. Furthermore, 
evidence for rare cancer predisposition syndromes should 
be included in S3 BC guidelines.
Due to the risk of contralateral BC in P/LP TP53 ger-
mline variant carriers described in literature,2,15,17 CPM 
might be justifiable in case of primary unilateral BC.22 
This corresponds to the high rate of contralateral BC in 
our cohort. In a study using whole body MRI for baseline 
surveillance in individuals with LFS, Ballinger et al. de-
scribed that only two out of 264 women were diagnosed 
with BC. However, almost half of the study population 
had uni- or bilateral ME prior to study participation 
(n = 127/264, 48%) which might explain the low rate of BC 
or BC recurrence in their cohort.38 In our series, the rate 
of uni- or bilateral- MEs in primary BC was comparable 
with 51% (n = 18/35 ME performed) while we observed 
a significantly higher rate of locoregional recurrence and 
contralateral BC. It should be noted that there might have 
been a selection bias due to the inclusion- and genetic test-
ing criteria of the GC- HBOC or due to the fact that this 
cohort represents a volunteer cohort. Only one healthy 
carrier had a prophylactic bilateral ME in combination 
with a prophylactic PBSO while 19 women with primary 
or secondary BC underwent any kind of PO in our cohort. 
Saya et al. described a rate of 33.3% of female TP53 germ-
line P/LP variant carriers with risk- reducing operations 
or ME for previous BC.39 Our findings are in accordance 
with reported rates of CPM in P/LP BRCA1/2 variant car-
riers ranging between 0% and 49.3% while BC history, an 
aggregation of familial BC cases and a young age at can-
cer onset were predictive factors for bilateral risk- reducing 
ME or CPM.40– 43 Women opting for PO in our cohort were 
slightly older and most of them had a prior BC diagnosis. 
As LFS- BC often occurs below the age of 31, prophylactic 
surgery might be even justifiable before the age of 30 in 
healthy women meeting classical LFS criteria. In the case 
of BC, therapeutic and CPM should be considered as an 
option especially for young women with BC and LFS after 
discussion of concurrent risks.
Our data suggest that surgical strategies might in-
fluence median time to ipsilateral and contralateral 
recurrence and thus survival times but further prospec-
tive studies are needed. In case of BCS ipsilateral BC 
re- occurred earlier compared to women treated with 
unilateral therapeutic ME. Additionally, women with a 
therapeutic ME alone suffered from contralateral recur-
rence earlier than women treated with therapeutic ME 
in combination with a CPM. Large scale studies in other 
BC populations have shown that surgical techniques such 
as nipple- sparing ME guarantee a high oncological safety 
with well- accepted cosmetic results which might justify 
prophylactic procedures in high- risk populations as in 
LFS patients. However, those conclusions for LFS patients 
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require larger studies as our cohort only included two 
women with nipple- sparing ME.44,45
We could demonstrate that satisfaction with surgical 
results was high and most study participants would even 
recommend it to family members presuming a legitimate 
procedure in terms of psychological and cosmetic aspects. 
While studies focusing on PO among TP53 germline vari-
ant carriers are missing, systematic reviews in subjects 
with other high penetrant BC genes such as BRCA 1 and 
2 described high satisfaction with PO, good quality of life 
and excellent cosmetic results whereupon 90% would re-
peat the surgical procedure 20 years postoperatively.40,46,47 
However, if postoperative complications and subsequent 
surgeries were performed, it had a negative perception of 
PO.48– 50 Prospective studies are desirable to address the 
best surgical technique and the respective satisfaction in 
women with LFS. The best medical and psychosocial out-
come e.g. overall survival, quality of life or patient's sat-
isfaction with surgical results and PO decisions shall be 
achieved.
Contrary to the current international guidelines four 
of our study participants underwent PBSO. In order 
to avoid unnecessary interventions, individuals with 
rare cancer predisposition syndromes should be coun-
selled in specialised centres where a multidisciplinary 
concept with evidence- based medicine and a broad 
expertise with respect to the underlying syndrome is 
available to avoid overtreatment and to offer maximum 
supportive care.
This study is limited by its small sample size and its 
retrospective character. In addition, in most participants, 
the LFS diagnosis was unknown prior to breast surgery. 
A prospective study is necessary in order to confirm our 
results and to investigate further detailed analysis such as 
nipple- sparing procedures or time between locoregional 
recurrence and radiation. Current studies are underway 
to better reflect the broad phenotypic spectrum associated 
with L/LP variants of TP53.51
5  |  CONCLUSION
Aggressive BC subtypes are detected among women with 
LFS. The surgical treatment and CPM may increase the 
time to a second BC diagnosis whereas larger studies are 
needed for further statements. Since LFS is a rare cancer 
predisposition syndrome, national and international tu-
mour registries are essential to achieve more profound, in-
dividualised and evidence- based statements for treatment 
options including prophylactic operations.52 Individual 
competing tumour risks and long- term medical as well as 
psychosocial outcome need to be taken into consideration 
in risk and preventive counselling.
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